2321 |
FMS RELATED TYROSINE KINASE 1 |
FLT1 |
FLT |
FLT-1 |
VEGFR-1 |
VEGFR1 |
165070 |
3763 |
ENSG00000102755 |
OTTHUMG00000016648 |
P17948 |
BE0000029 |
Vascular endothelial growth factor receptor 1 |
Vascular permeability factor receptor |
FRT |
Fms-like tyrosine kinase 1 |
Tyrosine-protein kinase FRT |
Tyrosine-protein kinase receptor FLT |
PA28180 |
VGFR1_HUMAN |
1812 |
NP_001153392 |
NM_001159920 |
VEGFR |
VEGFR1/2/3 |
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 PRECURSOR (EC 2.7.1.112) (VEGFR-1) (VASCULAR PERMEABILITY FACTOR RECEPTOR) (TYROSINE-PROTEIN KINASE RECEPTOR FLT) (FLT-1) (TYROSINE-PROTEIN KINASE FRT) (FMS-LIKE TYROSINE KINASE 1). [SOURCE:UNIPROT/SWISSPROT;A |
fms related receptor tyrosine kinase 1 |
T63966 |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
Target Subclass | Other |
Target Subclass | Kinase |
Transmembrane Helix Count | 1 |
Target Main Class | Receptors |
CancerCommons Reported Gene Name | VEGFR |
CancerCommons Reported Gene Name | FGFR3 and others (VEGFR) |
CancerCommons Reported Gene Name | VEGF, PDGF |
GuideToPharmacology Gene Category Name | Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family |
GuideToPharmacology Gene Category ID | 324 |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Human Readable Name | KINASE |
Interpro Type | Domain |
Human Readable Name | DRUGGABLE GENOME |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Interpro Acc | IPR001245 |
Uniprot Status | Swiss-Prot |
Gene Biotype | PROTEIN_CODING |
KINASE |
TYROSINE KINASE |
DRUGGABLE GENOME |
CLINICALLY ACTIONABLE |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
Details of the Assay for Interaction | Evaluated in a [<sup>32</sup>]p-ATP incorporation assay |
inhibitor (inhibitory) |
Notes | |
Novel drug target | Established target |
Trial Name | AV-951 |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
antagonist (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor 1 antagonist |
Direct Interaction | yes |
inhibitor (inhibitory) |
Notes | |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Reported Cancer Type | Prostate |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | Vatalanib |
Novel drug target | Established target |
Trial Name | vatalanib, PTK 787 |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
agonist (activating) |
Mechanism of Interaction | Vascular endothelial growth factor receptor 1 and 2 (Flt-1 and KDR) agonist |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Notes | |
Trial Name | MGCD265 |
Novel drug target | Established target |
inhibitor (inhibitory) |
Drug family | Pan-TK inhibitor |
Alteration | VEGFR1:over |
Alteration | VEGFR2:over |
inhibitor (inhibitory) |
Notes | |
Trial Name | BIBF-1120,Vargatef |
Novel drug target | Established target |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
n/a |
Trial Name | MP0112 |
Novel drug target | Established target |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | E7080 |
Novel drug target | Established target |
Notes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor 1 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Trial Name | XL647 |
Novel drug target | Established target |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Notes |
inhibitor (inhibitory) |
Notes | |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
Specific Action of the Ligand | Inhibition |
n/a |
Trial Name | E-10030 |
Novel drug target | Established target |
n/a |
Trial Name | telatinib |
Novel drug target | Established target |
inhibitor (inhibitory) |
Notes | |
Trial Name | cediranib, AZD2171,Recentin |
Novel drug target | Established target |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor 1 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
inhibitor (inhibitory) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
agonist (activating) |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor 1 inhibitor |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
inhibitor (inhibitory) |
n/a |
Trial Name | Muparfostat |
Novel drug target | Established target |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Details of the Assay for Interaction | Assayed using AMPK heterotrimeric complex containing α2, β1, γ1 subunits |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | Zactima |
Novel drug target | Established target |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Details of the Assay for Interaction | In a biochemical enzyme activity assay. |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
Reported Cancer Type | Prostate |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Details of the Assay for Interaction | Measuring inhibition of kinase activity in a biochemical assay. |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
FLT1 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
FLT1 | Gene Symbol |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
ENSG00000102755 | Ensembl Gene Id |
2321 | Entrez Gene Id |
FLT1 | Gene Symbol |
Target Subclass | Other |
Target Subclass | Kinase |
Transmembrane Helix Count | 1 |
FLT1 | Uniprot Gene Name |
ENSG00000102755 | Ensembl Gene Id |
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 | Uniprot Protein Name |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Human Readable Name | KINASE |
Interpro Type | Domain |
KINASE, DRUGGABLE GENOME |
2321 | Entrez Gene ID |
CancerCommons Reported Gene Name | VEGFR |
CancerCommons Reported Gene Name | FGFR3 and others (VEGFR) |
CancerCommons Reported Gene Name | VEGF, PDGF |
ENSG00000102755 | Ensembl Gene Id |
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 PRECURSOR (EC 2.7.1.112) (VEGFR-1) (VASCULAR PERMEABILITY FACTOR RECEPTOR) (TYROSINE-PROTEIN KINASE RECEPTOR FLT) (FLT-1) (TYROSINE-PROTEIN KINASE FRT) (FMS-LIKE TYROSINE KINASE 1). [SOURCE:UNIPROT/SWISSPROT;A | Description |
FLT1 | Display Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
3763 | HUGO Gene ID |
3763 | HUGO Gene Symbol |
fms related receptor tyrosine kinase 1 | HUGO Gene Name |
GuideToPharmacology Gene Category Name | Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family |
GuideToPharmacology Gene Category ID | 324 |
PA28180 | PharmGKB ID |
FLT1 | DrugBank Gene Name |
P17948 | UniProt Accession |
2321 | Entrez Gene Id |
VEGFR-1 | Gene Symbol |
2321 | Entrez Gene Id |
VEGFR1 | MyCancerGenome Gene Symbol |
VEGFR1 | MyCancerGenome Reported Gene Name |
ENSG00000102755 | Gene Symbol |
FLT1 | Ensembl Id |
DRUGGABLE GENOME |
2321 | Entrez Gene Id |
FLT1 | MyCancerGenome Gene Symbol |
VEGFR1/2/3 | MyCancerGenome Reported Gene Name |
FRT | GENE_SYMBOL |
VEGFR1 | GENE_SYMBOL |
FLT1 | GENE_SYMBOL |
Vascular endothelial growth factor receptor 1 | Gene Name |
P17948 | UniProt ID |
KINASE |
FLT1 | Gene Symbol |
CLINICALLY ACTIONABLE |
2321 | Gene ID |
FLT | dGene Synonym |
FLT-1 | dGene Synonym |
KINASE, TYROSINE KINASE |
FLT-1 | TTD Gene Abbreviation |
T63966 | TTD Target ID |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |